Amazon-Future case: Singapore tribunal begins hearing plea on Reliance Retail deal
SECTIONS
Share
Synopsis
This hearing will continue on Tuesday, while during the next two days, the bench will consider the request to lift the stay, people in the know said.
Agencies
A Singapore arbitration tribunal on Monday began hearing Future Group’s plea to lift the stay on the deal to sell its retail assets to Reliance Retail and exclude its flagship listed company as a party to the dispute with Amazon. The Singapore International Arbitration Centre (SIAC) in October last year had given an emergency award staying the FutureReliance transaction until it decided on Amazon’s challenge to the sale.
Amazon and Future group arbitration battle to resume in Singapore telegraphindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from telegraphindia.com Daily Mail and Mail on Sunday newspapers.
share:
This news release, issued by Johns Hopkins Medicine, describes a novel targeted immunotherapy approach. This new approach employs bispecific antibodies to treat cancer by eliciting a Tcell response against mutated p53. The researchers used the Highly Automated Macromolecular Crystallography (AMX) and Frontier Microfocusing Macromolecular Crystallography (FMX) beamlines to characterize the molecular structure of the proteins. AMX and FMX are beamlines at the National Synchrotron Light Source II (NSLS-II) a U.S. Department of Energy (DOE) Office of Science User Facility at Brookhaven National Laboratory. NSLS-II offers a comprehensive suite of life science research capabilities. Johns Hopkins media contacts: Amy Mone, 410-614-2915, amone@jhmi.edu, or Valerie Mehl, 410-614-2916, mehlva@jhmi.edu. Brookhaven Lab media contacts: Cara Laasch, 631-344-8458, laasch@bnl.gov or Peter Genzer, 631-344-3174, genzer@bnl.gov.
New cancer immunotherapy uses engineered T cells to target a common genetic alteration
Researchers developed a prototype for a new cancer immunotherapy that uses engineered T cells to target a genetic alteration common among all cancers. The approach, which stimulates an immune response against cells that are missing one gene copy, called loss of heterozygosity (LOH), was developed by researchers at the Ludwig Center, Lustgarten Laboratory and the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center.
Genes have two alleles, or copies, with one copy inherited from each parent. Cancer-related genetic alterations commonly involve the loss of one of these gene copies.